NCT01633255 2019-12-17
[18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
Clinical Trials
7 trialsNCT01571726 2019-12-16
Imaging Studies and the Development of Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT01492192 2017-11-01
RGD-PET-CT in Cancer Angiogenesis
Oxford University Hospitals NHS Trust
Phase 2 Terminated
NCT01961583 2016-03-01
[18F]Fluciclatide PET Imaging of Pazopanib Response
Asan Medical Center
Phase 2 Terminated
NCT00565721 2014-08-18
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
GE Healthcare
Phase 2 Completed
NCT02193672 2014-07-18
A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00918281 2014-06-09
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
GE Healthcare
Phase 2 Completed